These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 23535924)
1. Molecular imaging as a de-risking tool: coming into focus? Mullard A Nat Rev Drug Discov; 2013 Apr; 12(4):251-2. PubMed ID: 23535924 [No Abstract] [Full Text] [Related]
2. Central nervous system drug development, basic, and clinical research: thinking outside the box. Klein DF; Glick ID; Shader RI J Clin Psychopharmacol; 2011 Oct; 31(5):553-4. PubMed ID: 21869701 [No Abstract] [Full Text] [Related]
3. Structural modifications that alter the P-glycoprotein efflux properties of compounds. Hitchcock SA J Med Chem; 2012 Jun; 55(11):4877-95. PubMed ID: 22506484 [No Abstract] [Full Text] [Related]
4. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases. Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722 [TBL] [Abstract][Full Text] [Related]
6. An audience with...Luca Santarelli. Interview by Alexandra Flemming. Santarelli L Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274461 [No Abstract] [Full Text] [Related]
7. Clinical Trials in CNS--SMi's Seventh Annual Conference. 25-26 November 2008, London, UK. Sherwood D IDrugs; 2009 Feb; 12(2):84-6. PubMed ID: 19204879 [No Abstract] [Full Text] [Related]
8. Use of predictive models in CNS diseases. Gomeni R Curr Opin Pharmacol; 2014 Feb; 14():23-9. PubMed ID: 24565008 [TBL] [Abstract][Full Text] [Related]
9. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents. Cole PE; Schwarz AJ; Schmidt ME Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072 [TBL] [Abstract][Full Text] [Related]
11. Quality by design in lead optimization: a new strategy to address productivity in drug discovery. Rossi T; Braggio S Curr Opin Pharmacol; 2011 Oct; 11(5):515-20. PubMed ID: 21652263 [TBL] [Abstract][Full Text] [Related]
12. Is pharma running out of brainy ideas? Miller G Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165 [No Abstract] [Full Text] [Related]
14. An introduction to adaptive designs and adaptation in CNS trials. Dragalin V Eur Neuropsychopharmacol; 2011 Feb; 21(2):153-8. PubMed ID: 20888739 [TBL] [Abstract][Full Text] [Related]
15. Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide. Banks WA; Greig NH Future Med Chem; 2019 Mar; 11(6):489-493. PubMed ID: 30912980 [No Abstract] [Full Text] [Related]
16. Translational medicine 2006. Persiani S IDrugs; 2006 Apr; 9(4):253-5. PubMed ID: 16596476 [No Abstract] [Full Text] [Related]
17. Regulatory watch: Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective. Butlen-Ducuing F; Pétavy F; Guizzaro L; Zienowicz M; Haas M; Alteri E; Salmonson T; Corruble E Nat Rev Drug Discov; 2016 Nov; 15(12):813-814. PubMed ID: 27895328 [No Abstract] [Full Text] [Related]
18. European Neuroscience--Seventh Biennial FENS Forum. Hannan AJ IDrugs; 2010 Sep; 13(9):607-9. PubMed ID: 20799140 [TBL] [Abstract][Full Text] [Related]
19. Getting more mileage out of a tankful of new molecular entities? Cavalla D Drug Discov Today; 2004 Apr; 9(7):304-5. PubMed ID: 15037227 [No Abstract] [Full Text] [Related]
20. A role for fMRI in optimizing CNS drug development. Borsook D; Becerra L; Hargreaves R Nat Rev Drug Discov; 2006 May; 5(5):411-24. PubMed ID: 16604100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]